قالب وردپرس درنا توس
Home / Health / Turn your head, cough, submit your DNA: Your next physical may include genetic testing.

Turn your head, cough, submit your DNA: Your next physical may include genetic testing.



Anyone who has had an annual physical exam knows the routine.

Step on the scale to check your weight. Watch the blood pressure cuff inflate.

Now, at least one local health system wants to add another component to many standard visits: genetic testing.

Starting in April, NorthShore University HealthSystem wants to offer extensive genetic testing to 10,000 primary care patients to determine whether they are at higher risk of developing conditions such as breast cancer, colorectal cancer and heart disease. The tests could also help steer patients towards the most effective pain and depression medications based on their genetics.

It's a glimpse into what some say could be the future of primary care treatable diseases earlier. 23andMe, by offering their own tests and follow-up care. Patients will not have to pay for the genome sequencing, which will be offered as part of a pilot project with genetic testing company Color. If the pilot is successful, NorthShore could offer the tests to more patients, although it would be beyond the first 1

0,000.

South Dakota-based Sanford Health is starting offering broad-based testing for primary care patients has tested about 2,000 patients. Dr. Drs., Dr. med. Cassie Hajek, Physician Chair for the System's Precision Medicine Program.

"If we can identify risk factors, then we need "We're going out in the population and keeping people healthy," said Dr. Watson. Olufunmilayo Olopade, director of the Center for Clinical Cancer Genetics at the University of Chicago Medicine.

Rebecca Marsalli of Zion has already taken advantage of NorthShore's offer. About 1,000 NorthShore patients agreed to undergo genetic testing as part of an earlier, smaller program.

Marsalli occasionally has been tested in the past. But as a new mom, getting tested at the top of her to-do list.

Once you've learned more about what's happening in cancer, NorthShore has a doctor who focuses on cancer on breast health The 29-year-old now wants to be checked with mammograms and MRIs regularly.

The "waiting period was very ner ve-wracking, but now that I have the results, it's kind of empowering because I know what I need to do, "Marsalli said. "I think it's amazing."

Still, questions about integrating genome sequencing into primary care.

It's still unknown, for example, how much certain genetic mutations might actually increase a person's risk of getting a disease, said Amy Storm, President of the National Society of Genetic Counselors.

"It's really an exciting area, and there's a lot of promise, but there's a lot more to it "we're reporting back," said Storm, who is also a leader of the program at Geisinger.

GlaxoSmithKline announced last year that it invested $ 300 million in 23andMe as part of a collaboration aimed at 23andMe's data. The companies plan to share in a new way. 23andMe only shares' consumers' data with their permission, and when it is shared, it's not personally identifiable, the company has said.

Color, based in Burlingame, Calif., Does not sell patients' data, although consumers can choose Othman Laraki, CEO and co-founder of Color, said

Hulick said NorthShore wants to protect patients' genetic data just as it protects all medical information.

There's no guarantee, however, that patients may not have been asked to disclose some of the patients' medical records and belong to the patients what they learn when they apply for certain types of insurance. A federal law, the Genetic Information Nondiscrimination Act, prevents health insurers and employers from obtaining a results of a genetic test.

Some consumers have thus been diagnosed as having long-term care insurance , as well as Alzheimer's or Parkinson's.

NorthShore's test, however, does not want to be Hulick said.

"We're focusing on where there are more effective screening or preventing diseases," Hulick said. Northshore wants to offer the tests to patients at about one-third of its 30 primary care practices, which are mostly in the northern suburbs. Participants' blood samples wants to be sent to Color for testing.

NorthShore hopes to make the tests available to a broad swaths of primary care patients at the participating practices, though the health system is silent.

"We really believe that genomics is a critical piece of the patient's life." , Said Kristen Murtos, chief administrative and strategy officer at NorthShore.

l schencker@chicagotribune.com

Twitter @ lschencker


Source link